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Abstract. Purpose: The aim of the present report is to
describe abnormal 18F-fluorodeoxyglucose (FDG) accu-
mulation patterns in the pleura and lung parenchyma in a
group of lung cancer patients in whom lung infarction was
present at the time of positron emission tomography
(PET).
Methods: Between November 2002 and December 2003,
a total of 145 patients (102 males, 43 females; age range
38–85 years) were subjected to whole-body FDG PET for
initial staging (n=117) or restaging (n=11) of lung cancer
or for evaluation of solitary pulmonary nodules (n=17). Of
these patients, 24 displayed abnormal FDG accumulation
in the lung parenchyma that was not consistent with
the primary lesion under investigation (ipsilateral n=12,
contralateral n=9 or bilateral n=3). Without correlative
imaging, this additional FDG uptake would have been
considered indeterminate in differential diagnosis.
Results: Of the 24 patients who were identified as having
such lesions, six harboured secondary tumour nodules di-
agnosed as metastases, while in three the diagnosis of a
synchronous second primary lung tumour was established.
Additionally, nine patients were identified as having post-
stenotic pneumonia and/or atelectasis (n=6) or granulo-
matous lung disease (n=3). In the remaining six (4% of all
patients), a diagnosis of recent pulmonary embolism that
topographically matched the additional FDG accumulation
(SUVmax range 1.4–8.6, mean 3.9) was made. Four of these
six patients were known to have pulmonary embolism, and
hence false positive interpretation was avoided by cor-
relating the PET findings with those of the pre-existing
diagnostic work-up. The remaining two patients were har-
bouring small occult infarctions that mimicked satellite
nodules in the lung periphery. Based on histopathological
results, the abnormal FDG accumulation in these two
patients was attributed to the inflammatory reaction and
tissue repair associated with the pathological cascade of
pulmonary embolism.
Conclusion: In patients with pulmonary malignancies, syn-
chronous lung infarction may induce pathological FDG
accumulation that can mimic active tumour manifestations.
Identifying this potential pitfall may allow avoidance of
false positive FDG PET interpretation.
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Introduction.
18F-fluorodeoxyglucose positron emission tomography
(FDG PET) has an established role in the management
of pulmonary malignancies [1, 2]. The high sensitivity
of FDG PET permits accurate identification of disease
extension and hence minimises the need for additional
diagnostic procedures [3, 4]. However, a variety of in-
flammatory and benign disorders have been shown to
accumulate remarkable amounts of FDG, misleadingly
mimicking locoregional or distant tumour foci [5]. Dis-
proving false positive results may result in considerable
morbidity for the patient, especially if tissue sampling is
required.
In non-small cell lung cancer (NSCLC), locoregional
metastasis within the ipsi- or contralateral lung paren-
chyma is frequently observed. While isolated tumour
nodules within the ipsilateral lobe containing the primary
tumour are consistent with stage T4, metastatic deposits in
other pulmonary lobes are classified as stage IV, in-
consistent with curative surgical resection [6, 7]. Accord-
ingly, additional pathological FDG uptake in the lung
parenchyma distinct from the primary tumour localisation
must be considered seriously.
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The aim of the present report is to describe abnormal
FDG accumulation patterns in the pleura and lung paren-
chyma in a group of patients who were harbouring syn-
chronous lung infarctions in addition to diagnosed or
suspected pulmonary malignancy at the time of their
initial staging using PET.
Materials and methods
Patients
From November 2002 to December 2003, a total of 145 patients
(102 males, 43 females; age range 38–85 years) were subjected to
whole-body FDG PET scan for initial staging (n=117) or restaging
(n=11) of lung cancer or for evaluation of a solitary pulmonary
nodule (SPN) (Table 1). Unless otherwise requested for a research
protocol, interpretation of PET was usually done with full access to
clinical data, associated cross-sectional imaging studies and
histopathological results, if available. Abnormal FDG accumulation
was defined as tracer uptake exceeding that of the normal
mediastinal activity. Besides visual analysis, we performed semi-
quantitative measurements of the detected lesions by means of the
maximal standardised uptake value (SUVmax) normalised to body
weight. Twenty-four of the studied patients displayed abnormal
FDG accumulation patterns in the lung parenchyma that were not
consistent with the primary lesion under investigation (ipsilateral
n=12, contralateral n=9 or bilateral n=3). Pre-PET diagnostic work-
up of these 24 patients included contrast-enhanced CT of the chest
and upper abdomen with (n=7) or without (n=16) ventilation and/or
perfusion (V/Q) lung scintigraphy. One patient was referred to PET
after incidental detection of an SPN on pulmonary CT angiography
confirming pulmonary embolism. Since histopathological verifica-
tion was not always available for these additional FDG PET
findings, correlative imaging studies and patient outcome were
accepted as two complementary standards of reference.
PET protocol
To increase image quality and to suppress myocardial glucose
utilisation, patients were asked to fast for at least 6 h before
undergoing the FDG PET examination. Patients received an
intravenous injection of 300–400 MBq of FDG and rested for
40–50 min to allow organ uptake. Before PET scanning, patients
were encouraged to void to minimise activity in the bladder due to
renal excretion of FDG. Then, patients were transferred to the table
of the PET scanner. Fifty to sixty minutes after injection of FDG, a
static whole-body emission PET scan was initiated covering the
patient from the pelvic floor to the head. All images and data
acquisition were performed using an Advance NXi PET scanner
(GEMS), as previously described [3]. Image datasets were
reconstructed iteratively and attenuation correction was performed
using the 68Ge rotating sources algorithm.
Results
Among the 24 patients who were identified as having
additional foci of FDG accumulation in the lung paren-
chyma aside from the primary lesions under investigation
(Table 1), six were harbouring secondary tumour mani-
festations consistent with M1 (contralateral, n=5; bilateral,
n=1) while three patients with contralateral additional
FDG uptake were diagnosed as having a synchronous
second primary lung cancer. These findings were verified
by histopathological examination (n=4) or correlative CT
scanning together with final outcome (n=5). Additionally,
nine patients were identified as having post-stenotic pneu-
monia and/or atelectasis (n=6) or granulomatous lung
disease (ipsilateral n=1, contralateral n=1 or bilateral n=1).
Although the diagnosis of these abnormalities was basi-
cally dependent on CT, pathological examination con-
Table 1. Clinical indications for PET, distribution of the additional foci of FDG uptake (per patient) and final diagnoses or outcome
Indication for
FDG PET
FDG PET results Additional FDG uptake in the lung Final diagnoses/outcome
(n=145)
Malignant
(n=9)
Inflammatory
(n=9)
Lung infarction
(n=6)
Tumour staging
(n=117)
Potentially
resectable
(n=79)
Non-resectable
(n=38)
Contralateral
(n=7)
Bilateral
(n=1)
Ipsilateral
(n=5)
Ipsilateral
(n=3)
Bilateral
(n=1)
Stage I–IIIa
(n=72)a
Stage IIIb–IV
(n=45)a
Tumour restaging
(n=11)
Metabolically
inactive
(n=3)
Metabolically
active (n=8)
Contralateral
(n=1)
– – In remission
(n=3)
Residual/
recurrent
(n=8)
Evaluation of an
SPN (n=17)
Non-FDG
avid (n=5)
FDG avid
(n=12)
– Ipsilateral
(n=2)
Contralateral
(n=1)
Bilateral (n=1)
Ipsilateral
(n=2)b
Benign
(n=6)
Malignant
(n=11)
SPN solitary pulmonary nodule
aFalse up-staging (n=4) was mainly related to reactive contralateral lymph nodes, whereas false down-staging (n=11) was associated with
contralateral microscopic nodal disease or cerebral metastases
bBased upon cytological examination, one patient was expected to have primary adenocarcinoma. However, wedge resection revealed only a
previously suspected “FDG-accumulating” lung infarction
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firmed these findings in three patients who underwent
thoracotomy.
Of the remaining six patients, four had previously been
identified as having thromboembolic lung disease no more
than 2 weeks before the PET scan, whereas the other two
had no such diagnosis at the time of their initial staging. In
the former four patients, who were diagnosed with (n=2)
or suspected of having (n=2) NSCLC, the diagnosis of
lung infarction located ipsilaterally (n=3) or bilaterally
(n=1) was established on the basis of the clinical pre-
sentation and lung scintigraphy (n=3) or pulmonary CT
angiography (n=1). In these four patients, the topographic
distribution of the secondary FDG uptake, in each case at
the lung periphery, was in accordance with that of the
known pulmonary embolism, and thus suggested accu-
mulation at the site of the embolus. For these lesions,
SUVmax ranged from 1.4 to 8.6 (mean 3.5). One patient, in
whom cytology revealed abnormal cells possibly consis-
tent with adenocarcinoma, underwent a thoracoscopic re-
section of a peripheral lesion considered as a pulmonary
infarct on the basis of V/Q and CT scan (Fig. 1). This
diagnosis was histopathologically confirmed; no malig-
nant cells were found.
The other two patients displayed four isolated foci of
peripheral FDG accumulation in the lung parenchyma of
the right upper lobe. The SUVmax of these four lesions
ranged from 3.8 to 5 (mean 4.4). At the time of the PET
scan, these two patients were harbouring a centrally located
primary tumour that extended to the right upper lobe. Since
neither the clinical picture nor the contrast-enhanced CT
suggested the existence of pulmonary embolism in either
patient, our provisional diagnosis was consistent with dis-
tally located satellite tumour nodules in the right upper lobe
(i.e. stage T4) and/or involvement of the pleura. These two
patients were subjected, however, to curative surgical re-
section since FDG PET identified neither mediastinal
lymph node involvement nor distant metastases. Ensuing
histopathological examination revealed that these isolated
peripheral foci of FDG uptake were consistent with lung
infarction; there was accompanying haemorrhagic inflam-
mation of the pleura in one patient (Fig. 2), while the other
had isolated lung infarction. In both, inflammatory changes
and myofibroblastic proliferation were surrounding these
lung infarctions (Fig. 2D). Additionally, proximal throm-
botic changes of the pulmonary artery were identified, as
well as an angiosarcoma in one patient and squamous cell
carcinoma invading the superior branch of the pulmonary
artery in the other.
The identification of FDG-avid infarction sequelae in
the aforementioned six patients had no impact on man-
agement: four patients with ipsilateral (n=3) or bilateral
(n=1) lung infarction (known, n=2, or occult within the
primary tumour lobe, n=2) were subjected to pneumonec-
tomy (n=1), lobectomy (n=1) or wedge resection (n=2).
Postoperative histopathological examination confirmed ma-
lignant pulmonary tumours in three of them. In the fourth
patient with suspected lung infarction and atypical ipsilateral
cells at cytology, wedge resection confirmed the diagnosis
Fig. 1 A Coronal FDG PET in a 71-year-old male patient, known
to have chronic thromboembolic lung disease, showing peripheral
FDG accumulation in the upper lobe of the right lung (arrows;
SUVmax 3.3). B Correlative subsegmental perfusion defect (arrow)
on the coronal 99mTc-MAA perfusion single-photon emission com-
puted tomography (SPECT) image. C Subpleural wedge-shaped
opacity (arrows) on CT consistent with lung infarction
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of infarction (Fig. 1); no malignant tissue was found. A
non-FDG-avid SPN in another low-risk patient, with ip-
silateral lung infarction, remained stable on subsequent
CT follow-up. The remaining patient with lung infarction-
induced ipsilateral additional uptake was not subjected to
curative surgery because of distant metastases.
Discussion
Diagnostic pitfalls inherent in FDG PET represent an
obvious limitation of functional imaging. Consequently,
direct correlation of PET findings with those obtained
from cross-sectional structural modalities such as CT or
MRI has been advocated to add a high level of specificity
to lesion categorisation [8, 9]. Nonetheless, consideration
of the patient’s clinical data (if any are available) may
allow many erroneous diagnostic pathways to be avoided.
Synchronous pulmonary embolism in patients with lung
cancer is not uncommon (prevalence of 3% in our study
population). Currently, there is no single best test to assure
the diagnosis of pulmonary embolism [10, 11]. Further-
more, the significant overlap of symptoms among differ-
ent thoracic pathologies may be misleading; in other
words, cough, dyspnoea, haemoptysis or chest pain in a
patient with lung cancer is most often attributed to the
existing neoplasia.
Degradation products of cross-linked fibrin (D-dimer)
are known to be highly sensitive but poorly specific in
detecting pulmonary embolism. In fact, D-dimer can be
elevated in up to 86% of patients with NSCLC [12]. A
normal plasma value can thus exclude with very high
probability the existence of venous thromboembolic dis-
ease, especially in patients with lung cancer [12, 13].
However, a D-dimer test is not necessarily performed in
the absence of clinical symptoms; consequently, silent
pulmonary embolism is invariably liable to be missed.
To the best of our knowledge, this is the first report to
characterise pathological FDG accumulation in the sequel-
ae of lung infarction. In this series, six patients diagnosed
with or suspected of having pulmonary malignancy dis-
played additional foci of FDG accumulation in the lung
parenchyma that topographically matched proven sites of
lung infarctions; all of the additional foci were located at the
lung periphery. Four of these patients were known to have
pulmonary embolism, and hence erroneous interpretation
was avoided after correlating the PET findings with those
obtained from the pre-existing diagnostic work-up (Fig. 1).
These secondary parenchymal FDG accumulations showed
a wide range of SUVmax values (1.4–8.6), most probably
Fig. 2 A Coronal and B sagittal FDG PET in a 62-year-old female
patient showing a right hilar FDG-avid tumour (✻) selectively
extending to the upper lobe as well as isolated subpleural FDG
accumulations (SUVmax 5) in the lung apex (black arrows). C A
sagittally sectioned macroscopic specimen. D A corresponding
(haematoxylin–eosin stained) histological slice at the level of the
isolated apical FDG accumulations, revealing two small lung
infarctions (white arrows), an area of necrosis (x) surrounded by
active inflammatory and myofibroblastic proliferation zones (+),
and normal lung tissue (0). Based on these findings, the diagnosis of
pulmonary embolism-induced lung infarctions was established
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reflecting different healing phases after lung infarction; this
hypothesis is strengthened by the absence of similar FDG
uptake in the lungs of patients with older pulmonary em-
bolism (data not shown).
In a previous report, Hany et al. described the iatrogenic
occurrence of an FDG-avid pulmonary microembolism
caused by a dislodged blood clot from the injection site in
the patient’s peripheral vein [14]. This tiny thrombus,
which transferred and homed within the distal pulmonary
vasculature, gave rise to erroneous interpretation of FDG
PET. Furthermore, in a small series of nine patients with
septic thrombophlebitis, Miceli et al. observed strong FDG
uptake in the involved veins (SUV range, 3.8–21.4) that
resolved completely in six of the patients who underwent
subsequent PET scanning after appropriate antimicrobial
therapy [15]. Contrary to Hany et al.’s observation, our data
suggest that FDG uptake is not necessarily linked to the
thrombus itself but may also reflect postembolic changes in
the infarcted lung parenchyma and can thus indirectly lead
to false positive PET interpretation.
Two patients with occult lung infarction displayed
isolated peripheral FDG uptake in the upper lobe of the
right lung in addition to their ipsilateral primary tumour
manifestations (Fig. 2). Since neither the clinical picture
nor the CT findings suggested the existence of lung in-
farction in either patient, these FDG-avid foci were initially
interpreted as potential satellite nodules in the affected lung
lobe. Given the opinion that some cases of “local T4”
disease may benefit from aggressive surgical management
[16], both patients were considered operable after both
regional lymph node and distant metastases had been
excluded.
In the regions where FDG PET falsely indicated addi-
tional ipsilateral satellite nodules in the lung parenchyma,
histological examination revealed the existence of lung in-
farction, with or without complicating haemorrhagic inflam-
mation of the pleura (Fig. 2). It is of note that a remarkable
myofibroblastic proliferation zone and an overt inflamma-
tory reaction were observed around these infarctions. These
findings are in accordance with the known avidity of both
acute and chronic inflammatory infiltrates for FDG [17, 18].
Similarly, in an experimental model of lung injury, Chen and
co-workers observed that neutrophil activation is the source
of increased FDG uptake in acutely injured lungs [19]. This
is primarily related to the intrinsic activation of specific
glucose transporter molecules within the phagocytes [20].
It is well recognised that tumours that originate from or
encroach on a major vascular pedicle may lead to blood-
stream slowing and/or stagnation that may result in
thrombus formation. In the aforementioned two patients,
in addition to an angiosarcoma in one and a squamous cell
carcinoma that invaded the superior branch of the pul-
monary artery in the other, frank thrombotic changes of
the right main pulmonary artery (n=1) or its right upper
branch (n=1) were identified at histopathological exami-
nation. The arterial involvement had certainly contributed
to the pathogenesis of these occult lung infarctions, in con-
junction with the known paraneoplastic coagulation ab-
normalities associated with some pulmonary malignancies
[21].
The lownumber of patients identifiedwith lung infarction
showing FDG uptake certainly represents a limitation of the
present study. However, since histopathological verification
could be obtained in half of the patients (three of six), we
believe that our observations are constant and valid.
Conclusion
Recent lung infarction may show remarkable FDG uptake
and consequently can induce false interpretation of FDG
PET in patients with pulmonary malignancies. This is pri-
marily attributed to the inflammatory consequences of
abrupt pulmonary devascularisation. The existence of sub-
pleural foci of FDG uptake either unilaterally or bilaterally
in subjects with a history consistent with possible throm-
boembolic lung disease merits further diagnostic work-up.
Ventilation/perfusion SPECT might be the investigation of
choice in patients with peripheral lesions rather than CT
angiography. Furthermore, in patients with central pulmo-
nary malignancy possibly invading a pulmonary artery,
very peripheral FDG accumulation close to or involving the
pleura of the same lung may suggest lung infarction that
does not preclude curative surgical resection.
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